Cellectis S.A. (EPA:ALCLS)
2.496
+0.028 (1.13%)
Aug 3, 2026, 12:38 PM CET
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
€286,981
Profits / Employee
€256,866
Market Cap
179.18M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 229 | 7 | 3.15% | 224 | 5 |
| Dec 31, 2024 | 222 | 1 | 0.45% | 216 | 6 |
| Dec 31, 2023 | 221 | -16 | -6.75% | 216 | 5 |
| Dec 31, 2022 | 237 | -63 | -21.00% | 231 | 6 |
| Dec 31, 2021 | 300 | 19 | 6.76% | 294 | 6 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| DBV Technologies | 170 |
| Innate Pharma | 164 |
| Transgene | 145 |
| Adocia | 73 |
| OSE Immunotherapeutics | 64 |
| Sensorion | 63 |
| MaaT Pharma | 59 |
Cellectis News
- 3 days ago - Cellectis to Report Second Quarter Financial Results on August 6, 2026 - GlobeNewsWire
- 18 days ago - Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio - GlobeNewsWire
- 5 weeks ago - Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - GlobeNewsWire
- 7 weeks ago - Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewsWire
- 7 weeks ago - Cellectis Slides: FY 2026 - Filings
- 7 weeks ago - Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA - TheFly
- 7 weeks ago - Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL - GlobeNewsWire
- 2 months ago - Monthly information on share capital and company voting rights - GlobeNewsWire